Managing oral chemotherapy: The healthcare practitioner's role

American Journal of Health-System Pharmacy

Volumn 64, Issue 9 SUPPL., 2007, Pages

  Viele, Carol S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antineoplastic agents; Compliance; Dosage schedules; Drug administration; Drug administration routes; Drug interactions; Food; Health professions; Methodology; Neoplasms; Patient information; Patients; Sociology; Toxicity

Indexed keywords

ANTACID AGENT; ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; BEXAROTENE; CAPECITABINE; DASATINIB; ERLOTINIB; EXEMESTANE; GEFITINIB; HORMONE DERIVATIVE; IMATINIB; LAPATINIB; LENALIDOMIDE; MEGESTROL ACETATE; PLACEBO; SORAFENIB; SUNITINIB; TAMOXIFEN; THALIDOMIDE; VORINOSTAT;

ABDOMINAL PAIN; ALOPECIA; ANEMIA; ANKLE EDEMA; ANOREXIA; ARM SWELLING; ASTHENIA; BIRTH DEFECT; BLEEDING; BLISTER; BONE MARROW DEPRESSION; BREAST CALCIFICATION; CANCER; CANCER CHEMOTHERAPY; CEREBROVASCULAR ACCIDENT; CHEMOTHERAPY INDUCED EMESIS; CHOLESTEROL BLOOD LEVEL; CLINICAL DECISION MAKING; CLINICAL PRACTICE; CLINICAL TRIAL; CONJUNCTIVITIS; CONSTIPATION; DEEP VEIN THROMBOSIS; DEHYDRATION; DEPIGMENTATION; DIARRHEA; DIZZINESS; DROWSINESS; DRUG BIOAVAILABILITY; DRUG CONTRAINDICATION; DRUG COST; DRUG SAFETY; DRUG SELF ADMINISTRATION; DRY EYE; DRY SKIN; DYSLIPIDEMIA; DYSPNEA; EDEMA; FATIGUE; FEVER; FLUID RESUSCITATION; FLUID RETENTION; FOOT EDEMA; HAND FOOT SYNDROME; HEADACHE; HEALTH CARE PERSONNEL; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART RATE; HOT FLUSH; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOCALCEMIA; HYPOKALEMIA; HYPOPHOSPHATEMIA; HYPOTHYROIDISM; IMPOTENCE; INTERSTITIAL LUNG DISEASE; LEG EDEMA; LEG SWELLING; LEUKOPENIA; LIBIDO DISORDER; LONG TERM CARE; LUNG TOXICITY; MENSTRUAL IRREGULARITY; MUCOSA INFLAMMATION; MUSCLE CRAMP; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; PANCREAS CANCER; PATIENT COMPLIANCE; PATIENT EDUCATION; PATIENT MONITORING; PERIPHERAL EDEMA; PRESCRIPTION; PRIORITY JOURNAL; PRURITUS; QT PROLONGATION; RASH; REVIEW; ROLE PLAYING; SIDE EFFECT; SKIN DISCOLORATION; SKIN EXFOLIATION; STOMATITIS; THORAX PAIN; THROMBOCYTOPENIA; THROMBOSIS; TRIACYLGLYCEROL BLOOD LEVEL; UNSPECIFIED SIDE EFFECT; VAGINA BLEEDING; VAGINAL PRURITUS; VOMITING; WEAKNESS; WEIGHT GAIN;

EID: 34247562204     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp070037     Document Type: Review

References (31)

1. Kelly A, Agius CR. Improving adherence to endocrine therapies: the role of advanced practice nurses. Oncology (Nurse Edition). 2006; 20(10 suppl 7):50-4.
2. Partridge AH, Avorn J, Wang PS et al. Adherence to therapy with oral antineoplastic agents. J Natl Cancer Inst. 2002; 94:652-61.
3. Fink AK, Gurwitz J, Rakowski W et al. Patient beliefs and tamoxifen discontinuance in older women with estrogen receptor-positive breast cancer. J Clin Oncol. 2004; 22:3309-15.
4. Partridge AH, Wang PS, Winer EP et al. Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol. 2003; 21:602-6.
5. Cuzick J, Forbes J, Edwards R et al. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet. 2002; 360:817-24.
6. Love RR, Cameron L, Connell BL et al. Symptoms associated with tamoxifen treatment in postmenopausal women. Arch Intern Med. 1991; 151:1842-7.
7. Cameron C. Patient compliance: recognition of factors involved and suggestions for promoting compliance with therapeutic regimens. J Adv Nurs. 1996; 24:244-50.
8. Edelberg HK, Shallenberger E, Wei JY. Medication management capacity in highly functioning community-living older adults: detection of early deficits. J Am Geriatr Soc. 1999; 47:592-6.
9. Raehl CL, Bond CA, Woods T et al. Individualized drug use assessment in the elderly. Pharmacotherapy. 2002; 22:1239-48.
10. Shapiro CL, Recht A. Side effects of adjuvant treatment of breast cancer. N Engl J Med. 2001; 344:1997-2008.
11. Osborne CK. Tamoxifen in the treatment of breast cancer. N Engl J Med. 1998; 339:1609-18.
12. Aromasin package insert. New York, NY: Pharmacia & Upjohn; 2005 Oct.
13. McEvoy GK ed. Megestrol acetate. In: AHFS drug information 2006. Bethesda, MD: American Society of Health-System Pharmacists; 2006:1129-31.
14. Ignoffo R, Viele C, Damon L et al. A Cancer Chemotherapy Pocket Guide. Philadelphia, PA: Lippincott-Raven; 1998:198.
15. Xeloda package insert. Nutley, NJ: Roche Laboratories, Inc; 2006 Apr.
16. Targretin package insert. San Diego, CA: Ligand Pharmaceuticals, Inc; 2003 Apr.
17. Gleevec package insert. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2005 Nov.
18. Sprycel package insert. Princeton, NJ: Bristol-Myers Squibb Company; 2006 Jun.
19. Tarceva package insert. Melville, NY: OSI Pharmaceuticals, Inc; 2005 Nov.
20. Iressa package insert. Wilmington, DE: AstraZeneca Pharmaceuticals, LP; 2005 Jun.
21. Thalidomid package insert. Summit, NJ: Celgene Corporation; 2006 May.
22. Revlimid package insert. Summit, NJ: Celgene Corporation; 2006 Jun.
23. Nexavar package insert. West Haven, CT: Bayer Pharmaceuticals Corporation; 2006 Aug.
24. Sutent package insert. New York, NY: Pfizer Labs; 2006 Feb.
25. Zolinza package insert. Whitehouse Station, NJ: Merck & Co, Inc; 2006 Oct.
26. Wilkes GM, Doyle D. Palmar plantar erythrodysesthesia. Clin J Oncol Nurs. 2005; 9:103-6.
27. Lassere Y, Hoff P. Management of hand-foot syndrome in patients treated with capecitabine (Xeloda). Eur J Oncol Nurs. 2004; 8(suppl 1):S31-40.
28. Pérez-Soler R, Delord JP, Halpern A et al. HER1/EGFR inhibitor-associated rash: future directions for management and investigation, of outcomes from the HER1/EGFR inhibitor rash management forum. Oncologist. 2005; 10:345-56.
29. Yamamoto DS, Viale PH, Zhao G. Severe acneiform rash. Clin J Oncol Nurs. 2004; 8:654-6.
30. Dick SE, Crawford GH. Managing cutaneous side effects of epidermal growth factor receptor (HER1/EGFR) inhibitors. Community Oncol. 2005; 2:492-6.
31. Johnston SR, Leary A. Lapatinib: a novel EGFR/HER2 tyrosine kinase inhibitor for cancer. Drugs Today (Barc). 2006; 42:441-53.